Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 15/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 15/20 | 0.78 |
| ▸ | BRD4 | O60885 | 14/20 | 0.60 |
| ▸ | BRD2 | P25440 | 10/20 | 0.60 |
| ▸ | BRD3 | Q15059 | 10/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16618982 | 0.90 | BRD4 (0.65) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL16619413 | 0.88 | BRD4 (0.77) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL12168795 | 0.86 | CYP3A4 (0.86) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL16619571 | 0.86 | CYP3A4 (0.72) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| Hydrochloric Acid SCHEMBL1908118 | 0.86 | CYP3A4 (0.85) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL16618707 | 0.85 | CYP3A4 (0.59) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL16619401 | 0.84 | CYP3A4 (0.58) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL1903745 | 0.84 | CYP3A4 (0.81) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL12168779 | 0.83 | CYP3A4 (0.76) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL16619839 | 0.82 | BRD4 (0.59) | CYP3A4CYP2C9BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015049629-A1 | IMIDAZOQUINOLINE COMPOUNDS AS BROMODOMAIN INHIBITORS | Piramal Enterprises Limited (IN) | 2015-04-09 | — | — | WO | disclosed |